GILD logo Gilead Sciences +
Gilead Sciences
+

Gilead Sciences Overview

Company: Gilead Sciences
CEO: Daniel O'Day
Symbol: GILD
Exchange: NASDAQ
Industry: Drug Manufacturers - General
Sector: Healthcare
About

Gilead Sciences is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseaseslude Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, Gilead assists patients battling hematological disorders, various cancers, and those undergoing cell therapy, through products like Yescarta, Tecartus, Trodelvy, and Zydelig. Other specialized medicineslude Letairis, an oral drug for pulmonary arterial hypertension; Ranexa, also an oral medication, for chronic angina; and AmBisome, a liposomal formulation designed to combat serious invasive fungal infections. Gilead Sciences actively engages in collaboration agreements with a diverse range of partners to advance its therapeutic pipeline. Theselude Arcus Biosciences, Pionyr Immunotherapeutics, Tizona Therapeutics, Tango Therapeutics, Jounce Therapeutics, Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, and Merck & Co The company was founded in 1987 and its corporate headquarters are situated in Foster City, California.

Continue reading...

Gilead Sciences (GILD)

  • Stock Price
  • Volume
125.81 +57.73 +84.98%
Past 5 Years
  • 1D
  • 1W
  • 1M
  • 3M
  • 6M
  • YTD
  • 1Y
  • 2Y
  • 5Y
  • 10Y
  • ALL

Revenue

Gilead Sciences annual revenue was $29.44 B in 2025.

Net Income

Gilead Sciences annual net income was $8.51 B in 2025.

Employees

Gilead Sciences annual employee count was 17,000 in 2025.

Revenue by Segment

Gilead Sciences’s revenue by segment: Cell Therapy Products, Total Cell Therapy Product Sales: $2.18 B, Other Products, Total Other product sales: $799.00 M, Products, Other HIV: $20.75 B, Trodelvy: $1.40 B and Veklury: $911.00 M in 2025.

Revenue by Region

Gilead Sciences’s revenue by region: Europe: $5.06 B, Other International: $3.50 B and UNITED STATES: $20.88 B in 2025.

Executive Salary

Daniel P. O’Day Chairman and Chief Executive Officer, at Gilead Sc...

Revenue per Employee

Gilead Sciences revenue per employee was $1.73 M in 2025.

Profit per Employee

Gilead Sciences profit per employee was $500.59 K in 2025.

Income Statement

Operating Income

Gilead Sciences annual operating income was $11.82 B in 2025.

Research & Development

Gilead Sciences annual research & development expense was $5.69 B in 2025.

Tax Rate (%)

Gilead Sciences annual Tax Rate was 13.00% in 2025.

Assets & Liabilities | Cash Flow

Total Assets

Gilead Sciences annual total assets was $59.02 B in 2025.

Total Liabilities

Gilead Sciences annual total liabilities was $36.41 B in 2025.

Capital Expenditure

Gilead Sciences annual capital expenditures was - in 2025.

Ratios

Return on Equity (ROE)

Gilead Sciences annual return on equity(ROE) was 0.00% in 2025.

Return on Assets (ROA)

Gilead Sciences annual return on assets(ROA) was 0.00% in 2025.

Debt to Equity

Gilead Sciences annual debt to equity was 108.33% in 2025.

Profitability

Gross Profit Margin (%)

Gilead Sciences annual gross profit margin was 86.69% in 2025.

Operating Income Margin (%)

Gilead Sciences annual operating income margin was 40.14% in 2025.

Net Income Margin (%)

Gilead Sciences annual net income margin was 28.90% in 2025.

Earning Per Share

Gilead Sciences annual earning per share was $6.84 in 2025.

EBITDA

Gilead Sciences annual EBITDA was $10.82 B in 2025.

Free Cash Flow (FCF)

Gilead Sciences annual free cash flow(FCF) was $10.02 B in 2025.

Valuation

Enterprise value

Gilead Sciences annual enterprise value was - in 2025.

Enterprise value to Revenue

Gilead Sciences annual enterprise value to revenue was 0.00 in 2025.

Enterprise value to EBITDA

Gilead Sciences annual enterprise value to EBITDA was 0.00 in 2025.

Competitors’ Revenue

Frequently Asked Questions

Who is the CEO of Gilead Sciences?

Daniel O'Day is the CEO of Gilead Sciences.

What industry and sector is Gilead Sciences in?

Gilead Sciences operates in the Drug Manufacturers - General industry and the Healthcare sector.

What are Gilead Sciences's CIK, SIC, and ISIN codes?

  • CIK (Central Index Key): 0000882095
  • SIC (Standard Industrial Classification):
  • ISIN (International Securities Identification Number): US3755581036

Sign up for free to view

How many employees does Gilead Sciences have?

Gilead Sciences has 17,000 employees.

What is the revenue of Gilead Sciences?

In fiscal year 2025, Gilead Sciences generated a revenue of $29.44 Billion.

What is the net income of Gilead Sciences?

In fiscal year 2025, Gilead Sciences reported a net income of $8.51 Billion.

What is Gilead Sciences's biggest product segment?

Products, Other HIV is Gilead Sciences's biggest product segment, representing 79.69% of its total revenue.

When was Gilead Sciences listed on the stock exchange?

Gilead Sciences went public on Jan 22, 1992, through its Initial Public Offering (IPO), and it has been 34 years since then.

Sign up for free to view

What is the ticker symbol of Gilead Sciences, and where is it listed?

Gilead Sciences's ticker symbol is GILD, and the company is listed on the NASDAQ stock market exchange.

What is Gilead Sciences's current stock price?

Gilead Sciences's current stock price is $125.70 as of Jun 29, 2026.

What is Gilead Sciences's market capitalization?

As of , Gilead Sciences's market cap is .

What is Gilead Sciences's ranking in the world?

Ranked #12among 2,794 companies based on market cap.

Who are the top competitors of Gilead Sciences?

Competitors of Gilead Sciences include Eli Lilly and Company, Johnson & Johnson and AbbVie, and more.

People Also Search For

Submit feedback to Bullfincher